Trials / Completed
CompletedNCT04623021
A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
An Open-label, Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan) compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients diagnosed with COVID-19 pneumonia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nafamostat Mesilate | Administered intravenously as a continuous infusion |
Timeline
- Start date
- 2020-09-25
- Primary completion
- 2020-12-12
- Completion
- 2020-12-12
- First posted
- 2020-11-10
- Last updated
- 2021-02-02
Locations
11 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT04623021. Inclusion in this directory is not an endorsement.